Protocol No.: D933GC00001

Title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)
Principal Investigator
Pahuja, Shalu
Phase
III
Age Group
Adult
Applicable Disease Site
Gastrointestinal Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Lan Hu, BSN, MPH
Research Nurse
Phone: +1 304-293-6960

View on ClinicalTrials.gov